Precision Medicine

Backed by a proven billion-dollar impact model, 14 new startups are using AI, neuroscience, and philanthropy to revolutionize mental healthcare.

With its lead drug in Phase 3, Celldex will update investors at three major conferences, highlighting its immunology pipeline and financial strategy.

From its unique seat at the World Government Summit, CanSinoBIO unveils its next-gen vaccine pipeline and global strategy to fight humanity's oldest diseases.

With a promising spinal cord injury drug nearing late-stage trials, NervGen appoints interim leader Dr. Adam Rogers as permanent CEO to guide the breakthrough.

Heart disease is the leading cause of premature death for Canadian women, yet it remains under-diagnosed and under-treated. A national movement is fighting back.

Global giant CSL taps Swiss biotech Memo Therapeutics in a landmark deal, signaling a major shift from plasma to lab-grown immunotherapies.

Peijia Medical submits its innovative GeminiOne heart valve repair system for EU approval, signaling a new challenge to established players in the market.

Johnson & Johnson unveils promising data for its next-gen AFib tech while reinforcing the safety of its current platform in a competitive market.

A European company with Big Pharma roots brings its natural allergy aid, SnizIQ, to California, tapping into a growing demand for alternatives.

With rapid trial enrollment for a novel drug, Pulmovant offers a potential lifeline for patients with PH-ILD, a condition with few to no options.

A new 7,500-participant study will test a cfDNA-based screen to identify high-risk pregnancies months before symptoms appear, a potential paradigm shift.

Manipal's new comprehensive cancer centre in South Bengaluru integrates robotic surgery, precision radiation, and holistic support to combat rising cancer rates.

Viking Therapeutics' upcoming earnings call is about more than just financials. Investors are focused on key pipeline updates for its obesity and MASH drugs.

As Amwell prepares its 2025 results, investors watch to see if its strategic pivot to profitability can redefine the future of digital healthcare.

With a new focus on eye disease and fresh funding, Surrozen will present its novel Wnt-based pipeline to investors. What's at stake for the future of sight?

A new drug from Bayer dramatically cuts recurrent stroke risk by 26% without the dangerous bleeding side effects of current therapies, offering hope to millions.

A new study reveals why Sickle Cell Disease patients suffer from frequent crises and rely on pain pills, even with awareness of multi-million dollar cures.

A new initiative unites top scientists to study 'SuperAgers' and resilient brains, aiming to unlock the secrets of healthy aging and prevent Alzheimer's.

With major drug approvals on the horizon, Nuvalent's leadership will detail its strategy for its next-gen cancer therapies at an influential investor summit.

VectorY Therapeutics adds seasoned biotech architect Kevin Pojasek to its board, signaling a strategic push to accelerate its novel therapies for ALS and Alzheimer's.